Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal ranibizumab for macular edema due to central retinal vein occlusion (RAVO)
2006-005450-71Phase 3Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jan 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ranibizumab in central retinal vein occlusion with macular edema, sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Visual acuity at 8 weeks. Started Jan 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on 2006-005450-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005450-71.